These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 34568239)
1. Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases. Yücel BB; Aydog O; Nalcacioglu H; Yılmaz A Front Pediatr; 2021; 9():710501. PubMed ID: 34568239 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study. Babaoglu H; Varan O; Kucuk H; Atas N; Satis H; Salman R; Ozturk MA; Goker B; Tufan A; Haznedaroglu S J Clin Rheumatol; 2020 Jan; 26(1):7-13. PubMed ID: 30048391 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360 [TBL] [Abstract][Full Text] [Related]
4. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever. Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860 [TBL] [Abstract][Full Text] [Related]
5. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review. Eren Akarcan S; Dogantan S; Edeer Karaca N; Aksu G; Kutukculer N Rheumatol Int; 2020 Jan; 40(1):161-168. PubMed ID: 31273456 [TBL] [Abstract][Full Text] [Related]
6. Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever. Karabulut Y; Gezer HH; Öz N; Esen İ; Duruöz MT Rheumatol Int; 2022 Dec; 42(12):2211-2219. PubMed ID: 36048189 [TBL] [Abstract][Full Text] [Related]
7. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. Eroglu FK; Beşbaş N; Topaloglu R; Ozen S Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series. Sendogan DO; Saritas H; Kumru G; Eyupoglu S; Sadioglu RE; Tuzuner A; Sengul S; Keven K Transplant Proc; 2019 Sep; 51(7):2292-2294. PubMed ID: 31400972 [TBL] [Abstract][Full Text] [Related]
9. Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis. Kisla Ekinci RM; Balci S; Dogruel D; Altintas DU; Yilmaz M Paediatr Drugs; 2019 Oct; 21(5):389-395. PubMed ID: 31463794 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study. Tomokawa T; Koga T; Endo Y; Michitsuji T; Kawakami A Mod Rheumatol; 2022 Jul; 32(4):797-802. PubMed ID: 34897516 [TBL] [Abstract][Full Text] [Related]
11. Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine. Berdeli A; Şenol Ö; Talay G Eur J Rheumatol; 2019 Apr; 6(2):85-88. PubMed ID: 31365342 [TBL] [Abstract][Full Text] [Related]